REVIEW 3 major objections 9 minor 31 references
Characterization of DLBCL cell of origin-phenotypes based on tumor microenvironment features
T0 review · 3 major / 9 minor · reviewed 2026-07-08 · glm-5.2
Pith's one-line read ABC lymphoma tumors host distinct immune neighborhoods
desk verdict A well-built multiplexed imaging pipeline for DLBCL TME characterization, but the statistical framework cannot support the significance claims as written. read the letter →
The pith
A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.
The reading
What carries the argument
The pipeline combines Cellpose-based nuclear segmentation, Otsu-thresholded marker binarization for cell-type classification, centroid-distance proximity graphs for spatial interaction analysis, and distribution-summary morphological features (area, eccentricity, circularity, etc.) aggregated into per-sample feature vectors. The Hans classifier serves as the reference subtype assignment against which all TME features are compared.
What would settle it
If the Otsu thresholds do not correspond to biologically meaningful positivity boundaries, the cell-type labels — and therefore all composition, interaction, and morphology-by-cell-type results — could be artifacts of thresholding rather than reflections of genuine TME differences between GCB and ABC tumors.
Extended reading notes
Core claim
The central finding is that GCB and ABC DLBCL subtypes, classified by the Hans algorithm based on tumor-cell protein markers, also differ sharply in the composition, spatial organization, and morphology of surrounding non-tumor cells. ABC tumors carry a richer immune infiltrate with preferential M2-macrophage–tumor-cell contact, while GCB tumors are comparatively immune-sparse. The morphological features of M2-macrophages and CD8+ T-cells are among the strongest statistical discriminators between the two subtypes, suggesting that single-cell shape characteristics carry subtype-distinguishing information beyond what cell counts alone provide.
Load-bearing premise
The pipeline uses Otsu's thresholding method to binarize each cell's protein-expression signal into positive or negative for each marker. Otsu assumes the signal distribution splits into two clear groups, but fluorescence intensities in multiplexed imaging are often continuous rather than bimodal. If the threshold mislabels cells — for instance, calling a cell CD20-positive when it is not — every downstream cell-type proportion, interaction count, and morphological comparison
Signed reviews
Editorial analysis
A structured set of objections, weighed in public.
Referee Report
Summary. The manuscript presents a deep learning-based pipeline for analyzing multiplexed immunofluorescence images of DLBCL tumor microarrays. The pipeline segments nuclei (Cellpose), classifies cells into 10 types using Otsu-thresholded marker expression, and extracts 470 features per tissue sample spanning morphology, cell-type proportions, and spatial interaction patterns. These features are compared between GCB and ABC subtypes (as defined by the Hans classifier) using Mann-Whitney U tests. The authors report that ABC tumors are immune-rich with preferential M2-macrophage interactions, while GCB tumors are immune-poor, and identify morphometric differences in M2-macrophages and CD8+ T-cells as the most discriminating features. The pipeline is modular and the dataset (106 patients, 559 tissue samples, 14 markers) is substantial.
Significance. The study provides a useful, modular computational framework for quantitative TME characterization from multiplexed imaging data, and the DLBCL cohort is reasonably sized. The descriptive observations on cell-type composition differences between GCB and ABC subtypes (Fig. 2C, Fig. 3) are broadly consistent with published literature on immune-cold GCB and immune-hot ABC phenotypes. The label-permutation approach for assessing interaction enrichment is a sensible design choice. However, the formal statistical framework underlying the headline 'significantly different' claims has two load-bearing gaps that must be addressed before the central quantitative claims can be considered reliable.
major comments (3)
- §Results, 'Statistical analysis of aggregated features'; Fig. 4: The Mann-Whitney U tests are performed across 470 features (10 cell types × 5 morphological features × 7 distribution metrics + 10 cell proportions + 55 interaction features) with a p<0.05 threshold and no mention of multiple-testing correction (Bonferroni, Benjamini-Hochberg, or permutation-based FDR). At this threshold, approximately 23 features would be expected significant by chance alone. Several headline findings—morphometric differences in M2-macrophages and CD8+ T-cells, and specific cell interaction patterns—are drawn from these uncorrected tests. The authors should apply an appropriate multiple-testing correction and report which features survive.
- §Methods, 'DLBCL tissue cohort assembly'; §Methods, 'Feature Aggregation': The cohort comprises 106 patients with 'up to 3 tissue cores per patient' (559 total tissue samples), but the feature aggregation and statistical analysis refer to 'samples' without clarifying whether the unit of analysis is the patient or the individual core. If multiple cores from the same patient are treated as independent observations, pseudoreplication would inflate all p-values. The authors should state the unit of analysis explicitly and, if cores are used, either aggregate to patient level or use a mixed-effects model with patient as a random effect.
- §Methods, 'Data Extraction'; Table 4: Cell classification relies on Otsu thresholding of single-cell protein expression values to binarize each of the 11 markers. Otsu's method assumes a bimodal intensity distribution, but fluorescence signal distributions in multiplexed imaging are frequently continuous. If thresholds misclassify cells (e.g., calling a cell CD20+ when it is not), all downstream proportions, interaction analyses, and morphological comparisons are affected. The paper does not validate the Otsu thresholds against expert annotation, pathologist review, or any ground truth. The authors should provide at least a limited validation against manual annotation or justify the bimodality assumption with representative intensity histograms.
minor comments (9)
- §Methods, 'Spatial Organization of the DLBCLs': The proximity threshold d* = 0 is chosen 'based on qualitative analysis of graphs at various cutoffs.' A sensitivity analysis over a range of d* values, or at least a brief description of the qualitative criteria, would strengthen this choice and improve reproducibility.
- §Discussion, paragraph 3: The tumor cell definition (CD20+ with nuclear area ≥ 2× mean of CD20+ population) is introduced only in the Discussion. This is a load-bearing definition for several results and should be described in the Methods, with the nuclear area threshold listed as a parameter.
- Fig. 2C: The y-axis label and tick marks are unclear. Error bars or interquartile ranges should be specified in the figure legend.
- Fig. 3A: The color scale legend for the interaction enrichment heatmaps should be clarified—specifically, whether the color represents a z-score, log-fold change, or raw fraction of samples.
- Fig. 4B: The y-axes are labeled 'Arbitrary units' without further specification. For a statistical comparison figure, the axes should indicate the actual metric being plotted (e.g., U statistic, effect size).
- §Methods, 'Feature Aggregation': The text states '10 cell types, 5 morphological features and 7 distribution metrics, resulting in a vector of length 350,' but Table 6 lists 10 cell types including 'Other' and 'Tumor.' The total feature count of 470 (350 + 10 + 110) should be reconciled with the cell-type count used.
- Table 3: CD138, PD-L1, and CD56 are excluded due to poor staining quality, but the criteria for exclusion (e.g., signal-to-noise ratio threshold) are qualitative. A brief quantitative criterion or representative images would be useful.
- §Discussion, paragraph 5: The authors note that CD31 is expressed in monocytes and dendritic cells to a lesser extent, which could confound the endothelial cell classification. This limitation should also be acknowledged in the Methods or Results where endothelial interactions are reported.
- The manuscript would benefit from a data and code availability statement. If the pipeline code or processed data are available in a repository, this should be stated; if not, the authors should indicate how the pipeline can be accessed (e.g., upon request, pathologist review).
Simulated Author's Rebuttal
We thank the referee for a careful and constructive reading of our manuscript. The referee identifies three important methodological points: (1) the absence of multiple-testing correction across 470 features tested with Mann-Whitney U tests, (2) potential pseudoreplication arising from multiple tissue cores per patient, and (3) the lack of validation for Otsu-based cell classification thresholds. We agree with all three points and will address each in a revised manuscript. Specifically, we will apply Benjamini-Hochberg FDR correction and report surviving features, clarify the unit of analysis and re-run statistics at the patient level (aggregating cores), and provide validation of Otsu thresholds against expert pathologist annotation on a representative subset of images. We also provide below our honest assessment of what can and cannot be fully resolved within the scope of the current dataset.
read point-by-point responses
-
Referee: Mann-Whitney U tests across 470 features with p<0.05 threshold and no multiple-testing correction; approximately 23 false positives expected. Headline findings drawn from uncorrected tests.
Authors: The referee is correct. We performed 470 Mann-Whitney U tests without multiple-testing correction, and at a nominal p<0.05 threshold the expected number of false positives is indeed approximately 23. This is a genuine gap in our statistical framework. We will apply Benjamini-Hochberg FDR correction (q<0.05) to all 470 tests and report which features survive correction. We will update Figure 4 and the associated text to reflect corrected p-values, and we will revise all headline claims to reference only features that survive FDR correction. If certain features that we currently highlight do not survive correction, we will state this transparently and adjust our conclusions accordingly. We note that several of our findings—particularly the compositional differences shown in Figure 2C (cell-type proportions between GCB and ABC)—are broadly consistent with the published literature on immune-cold GCB and immune-hot ABC phenotypes, which provides external corroboration independent of our statistical testing. However, we agree that the formal statistical claims must rest on corrected tests. revision: yes
-
Referee: Unit of analysis unclear: 106 patients with up to 3 cores each (559 samples), but statistics refer to 'samples' without clarifying whether cores are treated as independent. Pseudoreplication would inflate p-values.
Authors: The referee raises a valid and important concern. In our current analysis, the unit of analysis is the individual tissue core (sample), not the patient. Multiple cores from the same patient were treated as independent observations. We agree that this constitutes pseudoreplication and could inflate our p-values. In the revised manuscript, we will aggregate features to the patient level by computing the median across cores from the same patient, and re-run all Mann-Whitney U tests (with FDR correction as addressed above) at the patient level (n=106). We will state the unit of analysis explicitly in the Methods. We will also report the number of patients with 1, 2, and 3 cores, respectively, so that the degree of within-patient sampling is transparent. We note that aggregating to patient level will reduce our effective sample size, which may reduce statistical power for some features. We will report which findings persist and which do not, and we will adjust our conclusions accordingly. revision: yes
-
Referee: Otsu thresholding assumes bimodal intensity distributions; fluorescence signals are frequently continuous. No validation against expert annotation or ground truth provided. Misclassification affects all downstream analyses.
Authors: The referee is correct that Otsu's method assumes a bimodal intensity distribution and that this assumption may not hold for all markers in multiplexed fluorescence imaging. We did not validate the Otsu thresholds against expert annotation, and this is a genuine limitation. In the revised manuscript, we will address this in two ways. First, we will provide representative intensity histograms for each marker so that readers can assess the bimodality assumption directly. Second, we will perform a limited validation: a board-certified pathologist (co-author R.B.) will manually annotate cell types on a representative subset of tissue regions (at least 5 cores covering both GCB and ABC subtypes), and we will compute agreement metrics (Cohen's kappa or similar) between manual annotation and our Otsu-based classification. We will report these validation results and discuss markers for which classification agreement is poor. We acknowledge that for markers with genuinely continuous distributions, Otsu thresholding may introduce systematic misclassification, and we will discuss this as a limitation. We note that our cell classification scheme uses combinations of markers (not single markers alone) for most cell types, which provides some robustness to threshold errors on individual markers, but this does not eliminate the concern. revision: yes
Circularity Check
No circularity: observational comparative study with externally defined group labels and independently extracted image features.
full rationale
This paper is an observational, comparative study—not a derivational one. The Hans classifier (an external pathology assessment) defines the GCB and ABC groups. The pipeline independently extracts TME features (cell proportions, morphology, spatial interactions) from multiplexed immunofluorescence images via segmentation (Cellpose), Otsu thresholding, and proximity graph construction. The statistical comparison (Mann-Whitney U tests) then tests whether these independently extracted features differ between the pre-defined Hans groups. No feature is defined in terms of the group labels, no parameter is fitted to one subset and then 'predicted' on closely related data, and no self-citation chain substitutes for a derivation. The concerns raised by the skeptic (multiple-testing correction, pseudoreplication, Otsu threshold validity) are correctness and methodology concerns, not circularity. The derivation chain is self-contained against external benchmarks.
Assumptions & free parameters
free parameters (3)
- Proximity threshold d* =
0
- Cytoplasm mask expansion =
25 pixels
- Tumor cell nuclear area threshold =
2x mean CD20+ nuclear area
assumptions (4)
- domain assumption Otsu's method produces biologically valid binary classifications of cell marker expression from fluorescence intensity distributions
- domain assumption The Hans classifier correctly assigns GCB/ABC labels to the patient samples
- domain assumption Nuclear morphology features are informative proxies for cell-level properties
- domain assumption Proximity graph edges at d*=0 represent biologically meaningful cell-cell interactions
Cite this review
Pith. "Pith review of Characterization of DLBCL cell of origin-phenotypes based on tumor microenvironment features." pith.science (2026). https://pith.science/paper/FDNJEHAL
@misc{pith2026260706129,
author = {Pith},
title = {Pith review of: Characterization of DLBCL cell of origin-phenotypes based on tumor microenvironment features},
year = {2026},
howpublished = {\url{https://pith.science/paper/FDNJEHAL}},
note = {Machine review of arXiv:2607.06129}
}
read the original abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with a high recurrence rate. The molecular profiling of DLBCL tumors culminated in several immunohistochemistry algorithms for prognostic stratification. Among those, the Hans classifier is widely used for classifying DLBCL into germinal center B-cell-like (GCB) and non-germinal center/activated B-cell-like (non-GCB/ABC) subtypes. The Hans classifier primarily evaluates protein expression of tumor-associated markers, however the tumor microenvironment (TME) of DLBCL includes a myriad of immune and stromal cells, cytokines, and extracellular matrix components that contribute to tumor growth, immune evasion, and recurrence rate. Although the Hans classifier provides a practical method for subtype identification, incorporation of TME information may improve risk stratification and further refine patient groups. Here, we present an unbiased deep learning-based approach to extract meaningful features from TME of DLBCL tumors for the automated processing and analysis of multiplexed images of a DLBCL patient cohort. Our pipeline quantifies a range of features that describe tumor sample cell composition, morphology, and its spatial organization. We point to alterations in the proportions of several cell populations between GCB and ABC tumors including increased immune cell proportions of the ABC and its preferential interaction with the M2-macrophages. Our analysis offers an in-depth characterization of the DLBCL subtypes and is exemplary of how our pipeline can be used for detailed quantitative analysis of a tumor and its subtypes.
Figures
Figures from the paper (1 more)
Reference graph
Works this paper leans on
-
[1]
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82
work page 2004
-
[2]
Nowakowski GS, Czuczman MS. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? American Society of Clinical Oncology Educational Book. 2015;35(1):e449-57
work page 2015
-
[3]
Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry
Reber R, Banz Y, Garamv¨ olgyi E, Perren A, Novak U. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry. Swiss medical weekly. 2013;143(1516):w13748-8
work page 2013
-
[4]
Molecular classification and therapeutics in diffuse large B-cell lymphoma
Shimkus G, Nonaka T. Molecular classification and therapeutics in diffuse large B-cell lymphoma. Frontiers in Molecular Biosciences. 2023;10:1124360
work page 2023
-
[5]
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge f¨ ur erwachsene Patient*innen mit einem diffusen großzelligen B-Zell-Lymphom und verwandten Entit¨ aten. AWMF; 2022. 1.0. AWMF-Registernummer: 018/038OL. Available from:https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/...
work page 2022
-
[6]
Lin JR, Izar B, Wang S, Yapp C, Mei S, Shah PM, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018;7
work page 2018
-
[7]
A pyramid approach to subpixel registration based on intensity
Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE transactions on image processing. 1998;7(1):27-41
work page 1998
-
[8]
Cellpose 2.0: how to train your own model
Pachitariu M, Stringer C. Cellpose 2.0: how to train your own model. Nature methods. 2022;19(12):1634-41
work page 2022
Show all 31 references
-
[9]
A threshold selection method from gray-level histograms
Otsu N, et al. A threshold selection method from gray-level histograms. Automatica. 1975;11(285-296):23-7
1975
-
[10]
Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma
Naji H, Hahn P, Pisula JI, Ugliano S, Simon A, B¨ uttner R, et al. Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma. BJC reports. 2025;3(1):34
2025
-
[11]
Histo-Miner: Deep Learning based Tissue Features Extraction Pipeline from H&E Whole Slide Images of Cutaneous Squamous Cell Carcinoma
Sanc´ er´ e L, Lorenz C, Helbig D, Persa OD, Dengler S, Kreuter A, et al. Histo-Miner: Deep Learning based Tissue Features Extraction Pipeline from H&E Whole Slide Images of Cutaneous Squamous Cell Carcinoma. arXiv preprint arXiv:250504672. 2025
2025
-
[12]
Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review
Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discover Oncology. 2025;16(1):184
2025
-
[13]
Genetic and epigenetic determinants of diffuse large B-cell lymphoma
Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood cancer journal. 2020;10(12):123
2020
-
[14]
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
Tumuluru S, Godfrey JK, Cooper A, Yu J, Chen X, MacNabb BW, et al. Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025;145(21):2460-72
2025
-
[15]
CD24 is a surrogate for ‘immune-cold’ phenotype in aggressive large B-cell lymphoma
Higashi M, Momose S, Takayanagi N, Tanaka Y, Anan T, Yamashita T, et al. CD24 is a surrogate for ‘immune-cold’ phenotype in aggressive large B-cell lymphoma. The Journal of Pathology: Clinical Research. 2022;8(4):340-54. Available from: https://pathsocjournals.onlinelibrary.wi...
2022 doi
-
[16]
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discovery. 2021 06;11(6):1468-89. Available from: https://doi.org/10.1158/2159-8290.CD-20-0839...
2021 doi
-
[17]
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature medicine. 2018;24(5):679-90
2018
-
[18]
Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma
Joldes C, Jimbu L, Mesaros O, Zdrenghea M, Fetica B. Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma. Biomedicines. 2025;13(5)
2025
-
[19]
Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas
Autio M, Br¨ uck O, Pollari M, Karjalainen-Lindsberg ML, Beiske K, Jørgensen JM, et al. Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas. Haematologica. 2025;110(6):1339-50
2025
-
[20]
A novel EZH1/2 dual inhibitor inhibits GCB DLBCL through cell cycle regulation and M2 tumor-associated macrophage polarization
An R, Zhang Z, Zhang D, Li Y, Lin Y, Sun H, et al. A novel EZH1/2 dual inhibitor inhibits GCB DLBCL through cell cycle regulation and M2 tumor-associated macrophage polarization. Journal of Biological Chemistry. 2024;300(11):107788. Available from: https://www.sciencedirect.co...
2024 doi
-
[21]
The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Lech´ e A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers. 2021;13(18)
2021
-
[22]
Functionally heterogeneous intratumoral CD4¡sup¿+¡/sup¿CD8¡sup¿+¡/sup¿ double-positive T cells can give rise to single-positive T cells
Li T, Ilano A, Arias-Badia M, Luong D, Chang H, Kwek SS, et al. Functionally heterogeneous intratumoral CD4¡sup¿+¡/sup¿CD8¡sup¿+¡/sup¿ double-positive T cells can give rise to single-positive T cells. Proceedings of the National Academy of Sciences. 2026;123(4):e2506168123
2026
-
[23]
CD4+CD8+ double-positive T cells in immune disorders and cancer: Prospects and hurdles in immunotherapy
Alam MR, Akinyemi AO, Wang J, Howlader M, Farahani ME, Nur M, et al. CD4+CD8+ double-positive T cells in immune disorders and cancer: Prospects and hurdles in immunotherapy. Autoimmunity Reviews. 2025;24(3):103757. Available from: https://www.sciencedirect.com/science/article/...
2025 doi
-
[24]
Legend or Truth: Mature CD4+CD8+ Double-Positive T Cells in the Periphery in Health and Disease
Hagen M, Pangrazzi L, Rocamora-Reverte L, Weinberger B. Legend or Truth: Mature CD4+CD8+ Double-Positive T Cells in the Periphery in Health and Disease. Biomedicines. 2023;11(10). Available from:https://www.mdpi.com/2227-9059/11/10/2702. doi:10.3390/biomedicines11102702
2023 doi
-
[25]
CD4+ CD8+ double positive (DP) T cells in health and disease
Parel Y, Chizzolini C. CD4+ CD8+ double positive (DP) T cells in health and disease. Autoimmunity Reviews. 2004;3(3):215-20. Available from: https://www.sciencedirect.com/science/article/pii/S1568997203001216. doi:https://doi.org/10.1016/j.autrev.2003.09.001
2004 doi
-
[26]
Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation
Huerga S, Ariceta B, Aguirre-Ruiz P, San Martin-Uriz P, Sarvide S, L´ opez-Janeiro A, et al. Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation. Blood. 2025;146(Supplement 1):3539-9
2025
-
[27]
Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature
Serna L, Azcoaga P, Brahmachary M, Caffarel MM, Braza MS. Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature. Frontiers in Immunology. 2023;Volume 14 - 2023
2023
-
[28]
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Ferrant J, Le Gallou S, Padonou F, Dubec-Fleury C, Leonard S, Papa I, et al. Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells. Blood Advances. 2026;10(4):1217-32. July 8, 2026 17/18
2026
-
[29]
Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8+ T-Cells Lacking the Hallmarks of Exhaustion
Greenbaum A, Gopal AK, Fromm JR, Houghton AM. Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8+ T-Cells Lacking the Hallmarks of Exhaustion. Blood. 2019 11;134(Supplement 1):1518-8
2019
-
[30]
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
Roider T, Baertsch MA, Fitzgerald D, V¨ ohringer H, Brinkmann BJ, Czernilofsky F, et al. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities. Nature Cell Biology. 2024;26(3):478-89
2024
-
[31]
Zheng B, Hu W, Fang Y, Li R. An Immune Exhaustion Signature Predicts Prognosis and Identifies diffuse large B cell lymphoma (DLBCL) Patients Who Derive Preferential Benefit from chimeric antigen receptor (CAR)-T cell Therapy. Cancer Pathogenesis and Therapy. 2026. Available fr...
2026 doi
Reviewed July 8, 2026 · model on record in the stance chip above.
Discussion (0). Continue with ORCID to comment.